GLP-1 / metabolic
Survodutide
In clinical trialsBI 456906 · GLP-1/glucagon dual agonist
Dual GLP-1/glucagon agonist targeting MASH and obesity.
What it is
An investigational once-weekly peptide co-agonizing GLP-1 and glucagon receptors, led by a focus on metabolic liver disease.
How it works
GLP-1 agonism curbs appetite and glycemia while glucagon activation raises energy expenditure and hepatic lipid metabolism.
Studied for
MASH/liver fibrosis, obesity, T2D.
Regulatory status
Investigational; not approved.
Safety
GI effects common, managed by titration; long-term liver/CV outcomes under study.
What the community reports about Survodutide
Aggregated from real community discussions across social platforms and forums. Anecdotal and self-reported — not causal, not medical advice.
The Boehringer Ingelheim GLP-1/Glucagon dual agonist (BI 456906) — Phase 3 development for obesity, T2D, and NASH/MASH (liver). Mechanism similar to Mazdutide; no FDA approval yet; corpus has no user-experience data.
Aggregated from public discussions and community forums, synthesized into themes and counts. Anecdotal and self-reported — not causal, not evidence a compound is safe or effective, not medical advice, and not a recommendation to use. No dosing shown.
Educational information only — not medical advice, and not a recommendation to use any compound. Many peptides here are not approved for human use; legal status and evidence quality vary and are noted above. This page contains no dosing information. Consult a qualified clinician before making any health decision.